Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$24.46 USD
-0.03 (-0.12%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $24.43 -0.03 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
MIRM 24.46 -0.03(-0.12%)
Will MIRM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MIRM
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Other News for MIRM
3 Potential Biopharma Buyout Targets
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Some Bubbles Are Starting To Pop
Stifel starts Mirum at buy, cites IBATi drug potential
Analyst Ratings For Mirum Pharmaceuticals